Takehisa Kawata Selected Research

Primary Hyperparathyroidism

7/2011	Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
10/2007	Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.
10/2007	Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
1/2006	Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism.
1/2006	Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
10/2005	Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takehisa Kawata Research Topics

Disease

16	Secondary Hyperparathyroidism 01/2022 - 09/2005
6	Chronic Renal Insufficiency 01/2020 - 10/2005
6	Primary Hyperparathyroidism 07/2011 - 10/2005
6	Uremia 10/2009 - 09/2005
4	Vomiting 01/2021 - 01/2018
4	Hyperparathyroidism 01/2018 - 10/2005
3	Vascular Calcification 01/2020 - 09/2005
3	Hyperphosphatemia 01/2018 - 10/2007
3	Parathyroid Diseases (Parathyroid Disorders) 10/2009 - 10/2007
2	Drug-Related Side Effects and Adverse Reactions 01/2022 - 01/2020
2	Hyperplasia 01/2020 - 07/2011
2	Nausea 01/2019 - 01/2018
2	Hypercalcemia (Milk Alkali Syndrome) 01/2018 - 10/2005
2	Hypophosphatemic Rickets 11/2009 - 04/2006
2	Hypophosphatemia 11/2009 - 04/2006
2	Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia) 11/2009 - 04/2006
2	Osteomalacia 11/2009 - 04/2006
1	Hypocalcemia 01/2022
1	Choristoma (Ectopic Tissue) 01/2020
1	Familial Hypophosphatemia (Phosphate Diabetes) 10/2007
1	Oncogenic osteomalacia 04/2006
1	Polyostotic Fibrous Dysplasia (McCune Albright Syndrome) 04/2006
1	Neoplasms (Cancer) 01/2006
1	Body Weight (Weight, Body) 10/2005
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 09/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2005

Drug/Important Bio-Agent (IBA)

12	Cinacalcet (Sensipar)FDA Link 01/2022 - 10/2005
10	Parathyroid Hormone (Parathormone)IBA 01/2022 - 09/2005
7	CalciumIBA 01/2022 - 10/2005
6	evocalcetIBA 01/2022 - 01/2018
5	Fibroblast Growth Factor-23IBA 01/2022 - 01/2006
5	Phosphates (Orthophosphate)IBA 01/2020 - 04/2006
4	Calcium-Sensing ReceptorsIBA 01/2020 - 10/2005
4	Cyclin D1IBA 07/2011 - 10/2005
3	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2022 - 01/2006
3	Pharmaceutical PreparationsIBA 01/2020 - 07/2009
2	Phosphorus (Red Phosphorus)IBA 01/2022 - 01/2020
2	1,25-dihydroxyvitamin DIBA 11/2009 - 10/2007
2	Vitamin D FDA LinkGeneric 07/2009 - 10/2007
1	EmeticsIBA 01/2021
1	Dialysis SolutionsIBA 01/2020
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2018
1	IonsIBA 01/2018
1	Hormones (Hormone)IBA 07/2011
1	AntibodiesIBA 11/2009
1	Therapeutic UsesIBA 11/2009
1	MineralsIBA 07/2009
1	Lactose FDA LinkGeneric 11/2008

Therapy/Procedure

7	Renal Dialysis (Hemodialysis) 01/2022 - 09/2005
1	Therapeutics 07/2009
1	Nephrectomy 11/2008
1	Parathyroidectomy 10/2005